Kowala-Piaskowska Arleta, Mozer-Lisewska Iwona, Pham Tram N Q, Michalak Tomasz I
Klinika Chorób Zakaźnych i Neurologii Dzieciecej, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań.
Postepy Biochem. 2010;56(4):383-8.
Hepatitis C virus (HCV) was discovered in 1989. HCV is a positive single-strand RNA. We all have thought, that HCV can replicate only in liver tissue, but now we know, that HCV can replicate in extrahepatic tissue as well. In about 48-86% of HCV infected patients, chronic hepatitis C (CHC) has been noticed and eventually, after tens of years, liver insufficiency, cirrhosis or hepatocellular carcinoma. The current recommended treatment for CHC is a combination of pegylated-interferon alpha and Ribavirin. Presently it is known, that HCV infection can persist as an occult infection. RNA HCV can be detected in patients after successful treatment for CHC or spontaneous elimination. Persistent HCV replication in hepatocytes or lymphoid cells would likely lead to continuous antigenic stimulation of the immune system. This prolonged replication may contribute to the immune tolerance of HCV, impairment of immune response and even further virus persistence. This occult infection grows more important in transplantation.
丙型肝炎病毒(HCV)于1989年被发现。HCV是一种正链单股RNA。我们曾经都认为,HCV仅能在肝组织中复制,但现在我们知道,HCV也能在肝外组织中复制。在约48%-86%的HCV感染患者中,已发现慢性丙型肝炎(CHC),最终,数十年后会出现肝功能不全、肝硬化或肝细胞癌。目前推荐的CHC治疗方法是聚乙二醇化干扰素α和利巴韦林联合使用。目前已知,HCV感染可作为隐匿性感染持续存在。在CHC成功治疗或自发清除后,患者体内可检测到RNA HCV。HCV在肝细胞或淋巴细胞中的持续复制可能会导致免疫系统持续受到抗原刺激。这种长期复制可能会导致HCV免疫耐受、免疫反应受损,甚至进一步导致病毒持续存在。这种隐匿性感染在移植中变得更加重要。